Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Restructuring Costs (2024 - 2025)

Historic Restructuring Costs for aTYR PHARMA (ATYR) over the last 2 years, with Q3 2025 value amounting to $3.9 million.

  • aTYR PHARMA's Restructuring Costs rose 3885.71% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year change of. This contributed to the annual value of $11.4 million for FY2024, which is 450.0% up from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Restructuring Costs is $3.9 million, which was up 3885.71% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Restructuring Costs registered a high of $3.9 million during Q2 2025, and its lowest value of $2.8 million during Q2 2024.